2021-11-16-世界卫生组织-Cervical_cancer_Cyprus_2021_country_profile_1页_64kb

Cyprus Cervical Cancer Profile Summary

Morbidity and Mortality

• Crude cervical cancer incidence per 100,000 women in 2020: Not provided.
• Age-standardized cervical cancer incidence per 100,000 women in 2020: Not provided.
• Cumulative risk of cervical cancer for ages 0-74 in 2020: Not provided.
• Cervical cancer deaths in 2019: 3,200.
• Cervical cancer mortality-to-incidence ratio in 2020: Not provided.
• Population-based cancer registry exists (based on 2021 data): Yes.
• Total female population in 2019: 599,000.
• Total female deaths in 2019: 3,200; crude mortality rate implied, but not fully detailed.

Primary Prevention

• HPV vaccination program coverage among girls (2020): 58% national coverage by 2021.
• HPV included in national vaccination programme: Yes.
• Scale of vaccination program: Programme coverage details available.
• Year of introduction: 2016.
• Primary target cohort: Girls aged 12-13 years for first dose.
• Vaccination coverage by age 15: 22% of girls turning 15 in 2020 received the final dose, meaning approximately 60% received their final dose before age 15.
• Related risk factors data provided where possible, but full details not specified; tobacco use prevalence among women aged 15+ (2020): 0.5%.Detailed program coverage: 58% coverage, ND for some specifics, but 100% target vaccinated by age 15 in some details.
• HIV incidence per 1000, women ages 15+ (2020): DA- high, but not fully detailed.

Secondary Prevention: Screening for Cervical Cancer

• National screening programme for cervical cancer exists (as of 2021): No.
• Primary screening test used (2021): Not provided.
• Target age range of programme (2021): Not specified.
• Programme/guidelines to strengthen early detection at primary health care level (2021): Not provided.
• Clearly defined referral system from primary to secondary and tertiary care (2021): Not provided.
• Screening coverage data: 20% screened in last 5 years among girls, detailed for women: 78% ever screened, 70% high-performance test by 35 and 45 years; screening coverage percentages vary.

Treatment and Supportive Care

• National guidelines on cervical cancer management exist (2021): Yes.
• Cancer diagnosis and treatment services availability based on numbers: Detailed numerically for various services, e.g., radiotherapy units (124 per 10,000 patients), brachytherapy units (292 per 10,000), hospital beds (18 per 10,000), etc.
• Cancer centre or department at tertiary level: Yes.
• Specific medical staff availability: Radiation oncologists (140), pathologists (14), surgeons (424), radiologists (14), medical physicists (14), nuclear medicine physicians (14).
• Palliative care available for non-communicable diseases: Yes, but annual opioid consumption data (e.g., in primary care) not fully detailed or not applicable; data on opioids excluded.

WHO Cervical Cancer Elimination Strategy Targets for 2030

• General targets mentioned in the WHO strategy context; as of the 2021 report, detailed progress and attainment were noted but not fully elaborated; note that elimination requires reducing incidence and mortality to below 4 per million and 4 per 100,000, respectively, with the data indicating areas for improvement.